SK Biopharmaceuticals Co., Ltd.
326030
Kedudukan dalam Saham
#4042
SK Biopharmaceuticals Co., Ltd. is a pharmaceutical enterprise dedicated to the... SK Biopharmaceuticals Co., Ltd. is a pharmaceutical enterprise dedicated to the research, identification, and development of novel therapies for central nervous system (CNS) disorders. Their product portfolio features Cenobamate, indicated for the treatment of epilepsy, and Solriamfetol, which addresses excessive daytime sleepiness experienced in conditions like narcolepsy or obstructive sleep apnea. The company's robust clinical pipeline includes Carisbamate, currently in Phase 1b/2 trials for Lennox-Gastaut syndrome, and Relenopride, advancing through Phase 2 for a rare neurological disease. Additionally, they have several candidates in Phase 1 development: SKL13865 for attention deficit/hyperactivity disorder (ADHD), SKL20540 for schizophrenia, SKL-PSY for bipolar disorder, and SKL24741, another potential treatment for epilepsy. Founded in 2011, the company is headquartered in Seongnam, South Korea, and functions as a subsidiary of SK Inc.
Harga Saham
$51.65
Modal Pasaran
$4.05B
Perubahan (1 hari)
0.27%
Perubahan (1 tahun)
-30.95%
Negara
KR
Perdagangan SK Biopharmaceuticals Co., Ltd. (326030)
Kategori
Healthcare
Sejarah pecahan saham untuk SK Biopharmaceuticals Co., Ltd. (326030)
Saham SK Biopharmaceuticals Co., Ltd. (simbol: 326030) telah mengalami sejumlah 0 pecahan saham.
Pecahan saham terkini berlaku pada Oct 21, 2026.
Satu saham 326030 yang dibeli sebelum Oct 21, 2026 kini bersamaan dengan 0 saham 326030.
Pecahan saham terkini berlaku pada Oct 21, 2026.
Satu saham 326030 yang dibeli sebelum Oct 21, 2026 kini bersamaan dengan 0 saham 326030.
Senarai pecahan saham
| Tahun | Pecahan | Gandaan | Gandaan Kumulatif |
|---|---|---|---|
| Tidak cukup data untuk tarikh yang disediakan. | |||
Pecahan saham untuk syarikat pesaing atau serupa
| Syarikat | Bilangan pecahan saham | Gandaan Kumulatif | Negara |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
CH
|
|
| 0 | - |
NL
|
